50 results on '"Palmero, Ramon"'
Search Results
2. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
3. An eHealth ecosystem for stepped and early psychosocial care in advanced lung cancer: Rationale and protocol for a randomized control trial
4. Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
5. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial
6. Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer
7. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
8. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
9. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
10. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
11. Severity of radiation pneumonitis, from clinical, dosimetric and biological features: a pilot study
12. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer
13. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
14. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
15. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
16. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer
17. IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen
18. Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer
19. Screening for epidermal growth factor receptor mutations in lung cancer
20. Encephalitis Induced by Immune Checkpoint Inhibitors
21. Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer
22. Severity of radiation pneumonitis, from clinical, dosimetric and biological features: a pilot study.
23. Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments
24. Abstract 449: Use of comprehensive cell-free circuating tumor DNA (cfDNA) analysis to identify genomic biomarkers in newly diagnosed advanced non-small cell lung cancer (NSCLC) patients
25. Prospective study of germline and somatic alterations for early onset lung cancer patients (EOLUNG MASTER protocol).
26. Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.
27. Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy
28. Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer.
29. Geriatric assessment to predict toxicity in elderly patients with unresectable locally advanced non-small-cell lung cancer treated with concurrent chemoradiotherapy.
30. Evolution and Clinical Impact of EGFRMutations in Circulating Free DNA in the BELIEF Trial
31. Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients
32. MA06.07 Impact of Type 2 Diabetes Mellitus and Its Metabolic Control on Prognosis of Unresectable Non-Small Cell Lung Cancer Patients
33. P2.02-010 Prognosis Impact of Oligoprogression Following Definitive Chemo-Radiotherapy in Stage III Non-Small Cell Lung Cancer
34. P2.03b-044 Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC
35. P2.05-054 Radiation Pneumonitis; Early Diagnosis and Protein Expression Profile in NSCLC Patients
36. Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy
37. A prospective study assessing the value of geriatric assessment in elderly patients with stage III NSCLC for concurrent chemoradiation.
38. Cost-utility analysis of first-line treatment with erlotinib versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer (NSCLC): economic analysis of EURTAC trial (O16.03)
39. Duloxetine in symptomatic chemotherapy-induced peripheral neuropathy: Single-center experience beyond the clinical trial.
40. Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).
41. Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).
42. Induction of an aggressive phenotype and poor survival in early-stage lung adenocarcinoma and epigenetic inactivation of microRNA-34b/c.
43. Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study.
44. High mRNA expression of LMO4, a BRCA1 downregulator, correlates with better prognosis in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.
45. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFRmutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
46. Mutations in the Antioxidant KEAP1/NRF2Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments
47. P2-242: First-line treatment with vinorelbine (VRL) plus cisplatin (CDDP) for patients with advanced non-small-cell lung cancer (NSCLC): Molecular correlates
48. Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy
49. P-596 Radiotherapy (RT) with concurrent paclitaxel plus carboplatin and paclitaxel administered as induction and consolidation chemotherapy (CT) in locally advanced non small cell lung cancer (NSCLC). Phase II trial
50. First-line treatment with vinorelbine (VRL) plus cisplatin (CDDP) for patients with advanced non-small-cell lung cancer (NSCLC): Molecular correlates.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.